CRISPR/Cas9 Engineered TIL for Enhanced Anti-Tumor Function

Time: 11:00 am
day: Conference Day 2

Details:

  • CRISPR/Cas9 screens identify top T cell targets enhancing the antitumor potency of engineered TIL (eTILTM) against solid tumors
  • Combination CRISPR screens (CRISPR2) determine the top T cell target combinations to further enhance the potency of eTILTM
  • KSQ-001 is a CRISPR/Cas9 engineered eTILTM

Speakers: